{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:08:46Z","timestamp":1784272126453,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2022-01188"],"award-info":[{"award-number":["2022-01188"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","award":["FO2025-0276"],"award-info":[{"award-number":["FO2025-0276"]}],"id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","award":["2023-0859"],"award-info":[{"award-number":["2023-0859"]}],"id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Methylphenidate (MPH) is a widely used psychostimulant for treating attention-deficit\/hyperactivity disorder (ADHD). Emerging epidemiological findings suggest that MPH treatment increases the risk of cardiovascular events. However, as causality could not be inferred, further investigation of the potential impact of MPH on human vascular endothelial function is warranted. We investigated the effects of MPH on human brain microvascular endothelial cells (HBEC) and human aortic endothelial cells (HAEC) across a range of concentrations, including those corresponding to therapeutic plasma levels, at 24 and 48\u2009h. Gene expression profiling of twenty-nine endothelial function-related genes was performed. Protein expression was assessed by ELISA, Western blotting, immunofluorescence and FACS, and barrier function was evaluated using FITC-dextran permeability and electric cell-substrate impedance sensing assays. Key endothelial markers with differential levels were analysed also in plasma from ADHD children (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200987) and adults (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009102), and matched controls (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20094 and\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200944, respectively). Exposure to MPH altered levels of several endothelial function-related genes. Across all concentrations tested, MPH increased the secretion of von Willebrand factor (vWF) and tissue plasminogen activator, whereas supratherapeutic concentrations 50\u2009\u00b5M and\/or 100\u2009\u00b5M MPH decreased Claudin-5 expression and impaired endothelial barrier integrity. In clinical plasma samples, children receiving MPH showed higher vWF levels compared with medication-na\u00efve children, but this was not observed in adult samples. Our findings suggest that acute exposure to therapeutic MPH concentration was associated with endothelial activation, and that supratherapeutic concentrations (50\u2009\u00b5M and\/or 100\u2009\u00b5M) may further compromise barrier integrity. These experimental outcomes may propose potential effects on vascular health associated with MPH use. Further studies are needed to confirm these findings.\n                  <\/jats:p>","DOI":"10.1038\/s41398-026-04237-6","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:47:45Z","timestamp":1784260065000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of methylphenidate on the human vascular endothelium"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9579-2842","authenticated-orcid":false,"given":"Wenjie","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaiBritt","family":"Giacobini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"\u00d6sterholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4987-2718","authenticated-orcid":false,"given":"Catharina","family":"Lavebratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"4237_CR1","first-page":"Cd009885","volume":"12","author":"OJ Storeb\u00f8","year":"2025","unstructured":"Storeb\u00f8 OJ, Storm MRO, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database Syst Rev. 2025;12:Cd009885.","journal-title":"Cochrane Database Syst Rev"},{"key":"4237_CR2","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/s41380-021-01391-9","volume":"27","author":"LC Farhat","year":"2022","unstructured":"Farhat LC, Flores JM, Behling E, Avila-Quintero VJ, Lombroso A, Cortese S, et al. The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit\/hyperactivity disorder in children and adolescents: a meta-analysis. Mol Psychiatry. 2022;27:1562\u201372.","journal-title":"Mol Psychiatry"},{"key":"4237_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S2215-0366(23)00042-1","volume":"10","author":"KKC Man","year":"2023","unstructured":"Man KKC, H\u00e4ge A, Banaschewski T, Inglis SK, Buitelaar J, Carucci S, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the attention deficit hyperactivity disorder drugs use chronic effects (ADDUCE) study. Lancet Psychiatry. 2023;10:323\u201333.","journal-title":"Lancet Psychiatry"},{"key":"4237_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2024.104209","volume":"101","author":"H Cho","year":"2024","unstructured":"Cho H, Lee K, Jeong YD, Udeh R, Acharya KP, Kang J, et al. Global burden of ADHD medication-associated cardiovascular disease, 1967-2023: a comparative analysis using the WHO pharmacovigilance database. Asian J Psychiatr. 2024;101:104209.","journal-title":"Asian J Psychiatr"},{"key":"4237_CR5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2215-0366(25)00062-8","volume":"12","author":"LC Farhat","year":"2025","unstructured":"Farhat LC, Lannes A, Del Giovane C, Parlatini V, Garcia-Argibay M, Ostinelli EG, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2025;12:355\u201365.","journal-title":"Lancet Psychiatry"},{"key":"4237_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/jcv2.12158","volume":"3","author":"L Li","year":"2023","unstructured":"Li L, Yao H, Zhang L, Garcia-Argibay M, Du Rietz E, Brikell I, et al. Attention-deficit\/hyperactivity disorder is associated with increased risk of cardiovascular diseases: a systematic review and meta-analysis. JCPP Adv. 2023;3:e12158.","journal-title":"JCPP Adv"},{"key":"4237_CR7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/jamapsychiatry.2023.4294","volume":"81","author":"L Zhang","year":"2024","unstructured":"Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D\u2019Onofrio BM, et al. Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. 2024;81:178\u201387.","journal-title":"JAMA Psychiatry"},{"key":"4237_CR8","doi-asserted-by":"publisher","first-page":"e241349","DOI":"10.1001\/jamanetworkopen.2024.1349","volume":"7","author":"M Garcia-Argibay","year":"2024","unstructured":"Garcia-Argibay M, B\u00fcrkner PC, Lichtenstein P, Zhang L, D\u2019Onofrio BM, Andell P, et al. Methylphenidate and short-term cardiovascular risk. JAMA Netw Open. 2024;7:e241349.","journal-title":"JAMA Netw Open"},{"key":"4237_CR9","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1111\/apa.70215","volume":"114","author":"H Elmowafi","year":"2025","unstructured":"Elmowafi H, Kindblom JM, Halldner L, Gyllenberg D, Naumburg E. Children and young adults who used medication for attention deficit hyperactivity disorder faced increased cardiac risks. Acta Paediatr. 2025;114:3021\u201333.","journal-title":"Acta Paediatr"},{"key":"4237_CR10","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/ehjcvp\/pvad028","volume":"9","author":"TE Eroglu","year":"2023","unstructured":"Eroglu TE, Halili A, Arulmurugananthavadivel A, Coronel R, Kessing LV, Fosb\u00f8l EL, et al. Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study. Eur Heart J Cardiovasc Pharmacother. 2023;9:658\u201365.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"4237_CR11","doi-asserted-by":"publisher","first-page":"Iii27","DOI":"10.1161\/01.CIR.0000131515.03336.f8","volume":"109","author":"J Davignon","year":"2004","unstructured":"Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109:Iii27\u201332.","journal-title":"Circulation"},{"key":"4237_CR12","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1161\/CIRCULATIONAHA.106.652859","volume":"115","author":"JE Deanfield","year":"2007","unstructured":"Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115:1285\u201395.","journal-title":"Circulation"},{"key":"4237_CR13","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","volume":"118","author":"MA Gimbrone Jr.","year":"2016","unstructured":"Gimbrone MA Jr., Garc\u00eda-Carde\u00f1a G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118:620\u201336.","journal-title":"Circ Res"},{"key":"4237_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.euroneuro.2020.10.005","volume":"41","author":"LL Yang","year":"2020","unstructured":"Yang LL, Stiernborg M, Skott E, S\u00f6derstr\u00f6m \u00c5, Giacobini M, Lavebratt C. Proinflammatory mediators and their associations with medication and comorbid traits in children and adults with ADHD. Eur Neuropsychopharmacol. 2020;41:118\u201331.","journal-title":"Eur Neuropsychopharmacol"},{"key":"4237_CR15","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.neubiorev.2003.08.013","volume":"27","author":"JM Swanson","year":"2003","unstructured":"Swanson JM, Volkow ND. Serum and brain concentrations of methylphenidate: implications for use and abuse. Neurosci Biobehav Rev. 2003;27:615\u201321.","journal-title":"Neurosci Biobehav Rev"},{"key":"4237_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00003088-200342040-00007","volume":"42","author":"JS Markowitz","year":"2003","unstructured":"Markowitz JS, Straughn AB, Patrick KS, DeVane CL, Pestreich L, Lee J, et al. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003;42:393\u2013401.","journal-title":"Clin Pharmacokinet"},{"key":"4237_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1373\/clinchem.2009.138396","volume":"56","author":"E Marchei","year":"2010","unstructured":"Marchei E, Farr\u00e9 M, Pardo R, Garcia-Algar O, Pellegrini M, Pacifici R, et al. Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. Clin Chem. 2010;56:585\u201392.","journal-title":"Clin Chem"},{"key":"4237_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13318-016-0346-1","volume":"42","author":"MD Cherm\u00e1","year":"2017","unstructured":"Cherm\u00e1 MD, Josefsson M, Rydberg I, Woxler P, Trygg T, Hollertz O, et al. Methylphenidate for treating ADHD: a naturalistic clinical study of methylphenidate blood concentrations in children and adults with optimized dosage. Eur J Drug Metab Pharmacokinet. 2017;42:295\u2013307.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4237_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/cap.2008.0128","volume":"20","author":"JR Stevens","year":"2010","unstructured":"Stevens JR, George RA, Fusillo S, Stern TA, Wilens TE. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation. J Child Adolesc Psychopharmacol. 2010;20:49\u201354.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"4237_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.euroneuro.2018.12.007","volume":"29","author":"V Coelho-Santos","year":"2019","unstructured":"Coelho-Santos V, Cardoso FL, Magalh\u00e3es A, Ferreira-Teixeira M, Leit\u00e3o RA, Gomes C, et al. Effect of chronic methylphenidate treatment on hippocampal neurovascular unit and memory performance in late adolescent rats. Eur Neuropsychopharmacol. 2019;29:195\u2013210.","journal-title":"Eur Neuropsychopharmacol"},{"key":"4237_CR21","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s00702-007-0759-8","volume":"114","author":"KV Gopal","year":"2007","unstructured":"Gopal KV, Miller BR, Gross GW. Acute and sub-chronic functional neurotoxicity of methylphenidate on neural networks in vitro. J Neural Transm. 2007;114:1365\u201375.","journal-title":"J Neural Transm"},{"key":"4237_CR22","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/15622970903176683","volume":"10","author":"M Bahcelioglu","year":"2009","unstructured":"Bahcelioglu M, Gozil R, Take G, Elmas C, Oktem H, Kadioglu D, et al. Dose-related immunohistochemical and ultrastructural changes after oral methylphenidate administration in cerebrum and cerebellum of the rat. World J Biol Psychiatry. 2009;10:531\u201343.","journal-title":"World J Biol Psychiatry"},{"key":"4237_CR23","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1007\/s00018-016-2301-3","volume":"73","author":"V Coelho-Santos","year":"2016","unstructured":"Coelho-Santos V, Socodato R, Portugal C, Leit\u00e3o RA, Rito M, Barbosa M, et al. Methylphenidate-triggered ROS generation promotes caveolae-mediated transcytosis via Rac1 signaling and c-Src-dependent caveolin-1 phosphorylation in human brain endothelial cells. Cell Mol Life Sci. 2016;73:4701\u201316.","journal-title":"Cell Mol Life Sci"},{"key":"4237_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.bbi.2020.05.056","volume":"89","author":"E Skott","year":"2020","unstructured":"Skott E, Yang LL, Stiernborg M, S\u00f6derstr\u00f6m \u00c5, R\u0215egg J, Schalling M, et al. Effects of a synbiotic on symptoms, and daily functioning in attention deficit hyperactivity disorder \u2013 A double-blind randomized controlled trial. Brain, Behav, Immun. 2020;89:9\u201319.","journal-title":"Brain, Behav, Immun"},{"key":"4237_CR25","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.3390\/nu15051293","volume":"15","author":"LL Yang","year":"2023","unstructured":"Yang LL, Stiernborg M, Skott E, Xu J, Wu Y, Landberg R, et al. Effects of a synbiotic on plasma immune activity markers and short-chain fatty acids in children and adults with ADHD-A randomized controlled trial. Nutrients. 2023;15:1293.","journal-title":"Nutrients"},{"key":"4237_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jpsychires.2022.09.042","volume":"156","author":"LL Yang","year":"2022","unstructured":"Yang LL, Stiernborg M, Skott E, Gillberg T, Landberg R, Giacobini M, et al. Lower plasma concentrations of short-chain fatty acids (SCFAs) in patients with ADHD. J Psychiatr Res. 2022;156:36\u201343.","journal-title":"J Psychiatr Res"},{"key":"4237_CR27","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s00431-025-06355-7","volume":"184","author":"OGA Behairy","year":"2025","unstructured":"Behairy OGA, El-Hamshary AM, Torky AA, Khashaba RA, Ali BG, Mohamed NF. Role of plasma Von-Willebrand factor in children with chronic liver diseases. Eur J Pediatr. 2025;184:532.","journal-title":"Eur J Pediatr"},{"key":"4237_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/00365519850186274","volume":"58","author":"A Nordenhem","year":"1998","unstructured":"Nordenhem A, Wiman B. Tissue plasminogen activator (tPA) antigen in plasma: correlation with different tPA\/inhibitor complexes. Scand J Clin Lab Invest. 1998;58:475\u201383.","journal-title":"Scand J Clin Lab Invest"},{"key":"4237_CR29","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1111\/jth.13696","volume":"15","author":"C Kawecki","year":"2017","unstructured":"Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost. 2017;15:1285\u201394.","journal-title":"J Thromb Haemost"},{"key":"4237_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cca.2005.12.030","volume":"368","author":"J Constans","year":"2006","unstructured":"Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. 2006;368:33\u201347.","journal-title":"Clin Chim Acta"},{"key":"4237_CR31","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.vph.2006.11.005","volume":"46","author":"B Tesfamariam","year":"2007","unstructured":"Tesfamariam B, DeFelice AF. Endothelial injury in the initiation and progression of vascular disorders. Vasc Pharmacol. 2007;46:229\u201337.","journal-title":"Vasc Pharmacol"},{"key":"4237_CR32","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1177\/0192623310378866","volume":"38","author":"J Zhang","year":"2010","unstructured":"Zhang J, Defelice AF, Hanig JP, Colatsky T. Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury. Toxicol Pathol. 2010;38:856\u201371.","journal-title":"Toxicol Pathol"},{"key":"4237_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100916","volume":"53","author":"A Low","year":"2019","unstructured":"Low A, Mak E, Rowe JB, Markus HS, O\u2019Brien JT. Inflammation and cerebral small vessel disease: a systematic review. Ageing Res Rev. 2019;53:100916.","journal-title":"Ageing Res Rev"},{"key":"4237_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1372355","volume":"12","author":"G Ferreira","year":"2024","unstructured":"Ferreira G, Taylor A, Mensah SA. Deciphering the triad of endothelial glycocalyx, von willebrand factor, and P-selectin in inflammation-induced coagulation. Front Cell Dev Biol. 2024;12:1372355.","journal-title":"Front Cell Dev Biol"},{"key":"4237_CR35","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/S0735-1097(02)02060-0","volume":"40","author":"JA Muldowney 3rd","year":"2002","unstructured":"Muldowney JA 3rd, Vaughan DE. Tissue-type plasminogen activator release: new frontiers in endothelial function. J Am Coll Cardiol. 2002;40:967\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"4237_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.tcb.2020.08.004","volume":"30","author":"T Otani","year":"2020","unstructured":"Otani T, Furuse M. Tight junction structure and function revisited. Trends Cell Biol. 2020;30:805\u201317.","journal-title":"Trends Cell Biol"},{"key":"4237_CR37","doi-asserted-by":"publisher","first-page":"7134","DOI":"10.1002\/jcp.30357","volume":"236","author":"H Chiba","year":"2021","unstructured":"Chiba H, Ichikawa-Tomikawa N, Imura T, Sugimoto K. The region-selective regulation of endothelial claudin-5 expression and signaling in brain health and disorders. J Cell Physiol. 2021;236:7134\u201343.","journal-title":"J Cell Physiol"},{"key":"4237_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107075","volume":"200","author":"Y Ling","year":"2024","unstructured":"Ling Y, Kang X, Yi Y, Feng S, Ma G, Qu H. CLDN5: from structure and regulation to roles in tumors and other diseases beyond CNS disorders. Pharmacol Res. 2024;200:107075.","journal-title":"Pharmacol Res"},{"key":"4237_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.bbi.2024.11.006","volume":"123","author":"Z Maridaki","year":"2025","unstructured":"Maridaki Z, Syrros G, Gianna Delichatsiou S, Warsh J, Konstantinou GN. Claudin-5 and occludin levels in patients with psychiatric disorders - A systematic review. Brain Behav Immun. 2025;123:865\u201375.","journal-title":"Brain Behav Immun"},{"key":"4237_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12987-019-0123-z","volume":"16","author":"C Greene","year":"2019","unstructured":"Greene C, Hanley N, Campbell M. Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS. 2019;16:3.","journal-title":"Fluids Barriers CNS"},{"key":"4237_CR41","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1002\/jcb.24118","volume":"113","author":"I Mandel","year":"2012","unstructured":"Mandel I, Paperna T, Volkowich A, Merhav M, Glass-Marmor L, Miller A. The ubiquitin-proteasome pathway regulates claudin 5 degradation. J Cell Biochem. 2012;113:2415\u201323.","journal-title":"J Cell Biochem"},{"key":"4237_CR42","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1161\/01.ATV.19.7.1796","volume":"19","author":"C Rosnoblet","year":"1999","unstructured":"Rosnoblet C, Vischer UM, Gerard RD, Irminger JC, Halban PA, Kruithof EK. Storage of tissue-type plasminogen activator in Weibel-Palade bodies of human endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:1796\u2013803.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4237_CR43","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.3390\/ijms22083850","volume":"22","author":"DJ Medina-Leyte","year":"2021","unstructured":"Medina-Leyte DJ, Zepeda-Garc\u00eda O, Dom\u00ednguez-P\u00e9rez M, Gonz\u00e1lez-Garrido A, Villarreal-Molina T, Jacobo-Albavera L. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021;22:3850.","journal-title":"Int J Mol Sci"},{"key":"4237_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.vph.2011.09.002","volume":"56","author":"J Zhang","year":"2012","unstructured":"Zhang J, Hanig JP, De Felice AF. Biomarkers of endothelial cell activation: candidate markers for drug-induced vasculitis in patients or drug-induced vascular injury in animals. Vasc Pharmacol. 2012;56:14\u201325.","journal-title":"Vasc Pharmacol"},{"key":"4237_CR45","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3390\/jcm9010175","volume":"9","author":"K Jansen","year":"2020","unstructured":"Jansen K, Hanusch B, Pross S, Hanff E, Drabert K, Bollenbach A, et al. Enhanced nitric oxide (NO) and decreased ADMA synthesis in pediatric ADHD and selective potentiation of NO synthesis by methylphenidate. J Clin Med. 2020;9:175.","journal-title":"J Clin Med"},{"key":"4237_CR46","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.niox.2023.06.006","volume":"138-139","author":"K Sinningen","year":"2023","unstructured":"Sinningen K, Emons B, B\u00f6hme P, Juckel G, Hanusch B, Beckmann B, et al. l-Arginine\/nitric oxide pathway and oxidative stress in adults with ADHD: Effects of methylphenidate treatment. Nitric Oxide. 2023;138-139:64\u20139.","journal-title":"Nitric Oxide"},{"key":"4237_CR47","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0731-7085(02)00196-6","volume":"29","author":"JK Huff","year":"2002","unstructured":"Huff JK, Davies MI. Microdialysis monitoring of methylphenidate in blood and brain correlated with changes in dopamine and rat activity. J Pharm Biomed Anal. 2002;29:767\u201377.","journal-title":"J Pharm Biomed Anal"},{"key":"4237_CR48","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40263-017-0409-0","volume":"31","author":"S Cortese","year":"2017","unstructured":"Cortese S, D\u2019Acunto G, Konofal E, Masi G, Vitiello B. New formulations of methylphenidate for the treatment of attention-deficit\/hyperactivity disorder: pharmacokinetics, efficacy, and tolerability. CNS Drugs. 2017;31:149\u201360.","journal-title":"CNS Drugs"},{"key":"4237_CR49","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1021\/acschemneuro.6b00199","volume":"7","author":"CJ Wenthur","year":"2016","unstructured":"Wenthur CJ. Classics in chemical neuroscience: methylphenidate. ACS Chem Neurosci. 2016;7:1030\u201340.","journal-title":"ACS Chem Neurosci"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04237-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04237-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04237-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:02:12Z","timestamp":1784271732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-026-04237-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4237"],"URL":"https:\/\/doi.org\/10.1038\/s41398-026-04237-6","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"8 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study was approved by the Regional Ethics Review Board in Stockholm (number 2015\/808-31\/2 and 2017\/91-31). All participants gave written informed consent prior to participation. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics declarations","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"369"}}